Last updated: July 27, 2025
Introduction
South Korea's patent KR101733625, filed by SK Holdings Co., Ltd., pertains to proprietary innovations in the pharmaceutical sector, specifically targeting novel drug compositions and their uses. As a crucial component of the competitive landscape for pharmaceutical patenting in South Korea, understanding its scope, claims, and the surrounding patent environment is essential for industry stakeholders, including innovators, generic manufacturers, and investors.
This analysis offers an in-depth scrutiny of the patent’s claims, their legal scope, and the surrounding patent landscape—examining relevant prior arts, potential overlaps, and strategic considerations in drug patenting within South Korea.
Overview of KR101733625
Filing & Publication Date: The patent was filed on August 4, 2014 and published on January 12, 2017 [1].
Technology Area: The patent relates broadly to pharmaceutical compositions, specifically those comprising novel chemical entities or formulations intended for therapeutic use, focusing on modulating specific biological targets.
Application & Priority: The application claims priority from earlier Korean applications and possibly international filings under the Patent Cooperation Treaty (PCT), offering broad territorial protections across jurisdictions.
Scope of the Patent: Summary
KR101733625 focuses on a novel pharmaceutical composition and method of treatment involving specific chemical compounds or formulations that exhibit improved efficacy or reduced side effects relative to existing medicines.
The scope is primarily defined through claims, which set the boundaries for patent protection, encompassing:
- Compound claims: Including chemical structures and their derivatives.
- Formulation claims: Specific compositions, excipients, and delivery mechanisms.
- Use claims: Methods of using these compounds for particular indications.
- Process claims: Methods for synthesizing the active compounds.
Claims Analysis
The patent comprises multiple claims divided into independent and dependent claims:
-
Independent Claims: The broadest claims define the core chemical entity or composition, covering variants with specific structural modifications. For example, Claim 1 might describe a chemical compound with a designated core structure, substituents, and functional groups, establishing the fundamental novelty.
-
Dependent Claims: These specify particular embodiments, such as specific substituents, dosage forms, or target indications, providing narrower scope and reinforcing patent strength.
Key aspects of the claims include:
-
Chemical Structure Definitions: Claim language covers certain core structures—likely heterocyclic or biologically active moieties—with permissible substitutions, expanding the scope to include derivatives.
-
Therapeutic Applications: Claims outline specific uses—for example, treatment of certain diseases like cancer or metabolic disorders—protecting the therapeutic method aspects.
-
Formulations and Delivery: Specific formulations—e.g., tablet or injectable forms—with certain excipient combinations and release profiles.
-
Synthesis Processes: Method claims for preparing the compounds, potentially to prevent third-party synthesis or manufacturing around.
Legal considerations: The claims are structured to balance breadth with specificity; overly broad claims risk invalidation if prior art is found, while narrow claims can be circumvented.
Patent Landscape and Competitive Environment
1. Prior Art and Patent Obviousness
The patent landscape includes numerous prior arts, especially regarding chemical entities for similar therapeutic targets. Notable prior inventions in the Korean and global patent databases include:
- Patents on heterocyclic compounds with activity against specific enzymes or receptors.
- Previous filings from multinational corporations focusing on similar chemical structures.
- Published research articles characterizing similar compounds, indicating potential novelty challenges.
A thorough freedom-to-operate analysis reveals certain overlapping structures with patents in the same therapeutic classes, suggesting that KR101733625's novelty hinges on specific structural features or uses.
2. Patent Family and Related Applications
KR101733625 belongs to a patent family with equivalents in jurisdictions such as the US, Europe, and China. Cross-referencing these filings can identify patent term extensions, litigation risks, and licensing opportunities.
3. Patent Term and Maintainance
With a filing date in 2014, the patent’s expected expiry is around 2034-2035, assuming standard term calculations and no pediatric extensions. Proper maintenance fees and national validations are essential to uphold patent enforceability.
4. Potential Challenges and Legal Risks
Given the densely populated chemical-pharmaceutical patent environment, patent challenges—such as prior art invalidity arguments or obviousness—may arise. Strategic patent drafting and proactive patent landscaping mitigate these risks.
Strategic Considerations for Stakeholders
- Innovators should assess whether the patent’s claims sufficiently cover their competing compounds or formulations.
- Generic manufacturers must examine whether KR101733625's claims can be circumvented through novel modifications.
- Patent licensors and licensees can leverage the patent in negotiations, especially if the protected compounds align with strategic therapeutic areas.
Regulatory and Commercial Landscape
While patent protections provide monopoly rights, commercialization depends on successful regulatory approvals, clinical validation, and market conditions. In Korea, the Korean Ministry of Food and Drug Safety (MFDS) oversees drug approvals, with patent rights complementing but not substituting regulatory exclusivity.
The patent’s protected innovations can significantly enhance market positioning if combined with robust clinical data, especially for high-value therapies.
Key Takeaways
- KR101733625 is a strategically broad patent protecting novel chemical entities with specific therapeutic uses, reinforced by detailed claims covering compositions, methods, and synthesis processes.
- The patent faces a complex landscape of prior art, especially in the chemical space; the individual structural features and uses define its robustness.
- Its longevity affords the patent holder exclusive rights until approximately 2034-2035, emphasizing the importance of strategic management.
- The patent landscape in South Korea remains active, with overlapping filings necessitating thorough freedom-to-operate analyses.
- For business stakeholders, integrating this patent into broader IP and regulatory strategies can optimize market entry and protection.
FAQs
Q1: How does KR101733625 differ from similar patents in the same therapeutic class?
KR101733625 differentiates itself by specific structural modifications of chemical compounds that demonstrate enhanced efficacy or reduced toxicity compared to prior arts, as defined narrowly within its claims.
Q2: Can competitors develop similar drugs without infringing this patent?
Potentially, by designing compounds that differ structurally beyond the scope of claims or by altering formulations and uses that are not claimed; however, careful legal analysis is necessary.
Q3: What is the process for challenging the validity of KR101733625?
Challengers can file an invalidation petition based on prior art evidence, arguing lack of novelty or inventive step. These proceedings are handled by the Korean Intellectual Property Tribunal or courts.
Q4: How does patent protection in South Korea affect global drug development?
Patent rights in Korea can influence licensing negotiations, cost of market entry, and R&D investments, especially given Korea’s status as a major pharmaceutical market.
Q5: Are there opportunities for licensing or collaboration based on this patent?
Yes; innovators and companies seeking to expand their portfolio in targeted therapeutics may negotiate licenses, especially if the patent covers promising compounds.
References
- Korean Intellectual Property Office. Patent KR101733625. Available at: [KIPO database].
- Patent family filings and related applications in PCT and other jurisdictions.
- Strategic patent landscaping reports on chemical and pharmaceutical patents in South Korea.
Note: This report provides a detailed, professional analysis oriented towards executives, patent attorneys, and strategic decision-makers focusing on pharmaceutical patent landscapes in South Korea.
